MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Sanofi

Slēgts

53.94 -1.01

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

53.77

Max

54.43

Galvenie mērījumi

By Trading Economics

Ienākumi

-2.3B

499M

Pārdošana

-6.5B

7.6B

P/E

Sektora vidējais

23.205

63.778

EPS

0.682

Dividenžu ienesīgums

3.67

Peļņas marža

6.539

Darbinieki

82,878

EBITDA

-3.7B

563M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+19.16% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.67%

2.39%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-1.5B

136B

Iepriekšējā atvēršanas cena

54.95

Iepriekšējā slēgšanas cena

53.94

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Sanofi Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 20. marts 06:43 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

2025. g. 3. febr. 13:19 UTC

Iegādes, apvienošanās, pārņemšana

L'Oreal to Sell $3.1 Billion Stake in Sanofi Back to Pharma Group -- Update

2025. g. 3. febr. 09:31 UTC

Iegādes, apvienošanās, pārņemšana

Correction to L'Oreal article

2025. g. 3. febr. 07:09 UTC

Iegādes, apvienošanās, pārņemšana

L'Oreal Agrees to Sell Back 2.3% Stake in Sanofi for $3.1 Billion

2025. g. 30. janv. 11:09 UTC

Peļņas

Correction to Sanofi Article

2025. g. 30. janv. 06:47 UTC

Peļņas

Sanofi Issues $5.2 Billion Share Buyback; Expects Sales, Core Earnings Growth

2025. g. 2. apr. 09:27 UTC

Karstas akcijas

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

2025. g. 20. marts 06:05 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi: Deal Seeks to Broaden Immunology Pipeline

2025. g. 20. marts 06:05 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

2025. g. 20. marts 06:04 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi to Pay $600M Upfront

2025. g. 20. marts 06:02 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

2025. g. 20. marts 06:00 UTC

Iegādes, apvienošanās, pārņemšana

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

2025. g. 19. febr. 06:35 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

2025. g. 19. febr. 06:34 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

2025. g. 19. febr. 06:34 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

2025. g. 19. febr. 06:33 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi to Remain Significant Shareholder in Opella Consumer Business

2025. g. 19. febr. 06:33 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

2025. g. 19. febr. 06:33 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi: This Follows Completion of Required Social and Corporate Procedures

2025. g. 19. febr. 06:32 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

2025. g. 19. febr. 06:31 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi, CD&R Sign Opella Share Purchase Agreement

2025. g. 3. febr. 06:37 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi Says Transaction Is Part of Its Share Buyback Program

2025. g. 3. febr. 06:35 UTC

Iegādes, apvienošanās, pārņemšana

L'Oreal: Sale Should Be Finalized in Coming Days

2025. g. 3. febr. 06:35 UTC

Iegādes, apvienošanās, pārņemšana

L'Oreal: Transaction Will Optimize Balance Sheet, Diversify Financing Sources

2025. g. 3. febr. 06:34 UTC

Iegādes, apvienošanās, pārņemšana

L'Oreal Says It Remains Important Sanofi Shareholder, Fully Supports Strategy

2025. g. 3. febr. 06:33 UTC

Iegādes, apvienošanās, pārņemšana

L'Oreal Will Own 7.2% of Sanofi's Capital, 13.1% of Voting Rights After Transaction

2025. g. 3. febr. 06:32 UTC

Iegādes, apvienošanās, pārņemšana

L'Oreal Selling 2.3% Stake in Sanofi for EUR101.50 a Share

2025. g. 3. febr. 06:31 UTC

Iegādes, apvienošanās, pārņemšana

L'Oreal to Sell Sanofi Stake for EUR3B

2025. g. 3. febr. 06:31 UTC

Iegādes, apvienošanās, pārņemšana

L'Oreal to Sell Sanofi Stake Back to Sanofi

2025. g. 30. janv. 10:47 UTC

Tirgus saruna
Peļņas

Sanofi's Buyback and Increased R&D Spending Are Positive -- Market Talk

2025. g. 30. janv. 10:31 UTC

Tirgus saruna
Peļņas

Sanofi's Lung Drug Beyfortus Sales Beat Stands Out Among 4Q Results -- Market Talk

Salīdzinājums

Cenas izmaiņa

Sanofi Prognoze

Cenas mērķis

By TipRanks

19.16% augšup

Prognoze 12 mēnešiem

Vidējais 64.75 USD  19.16%

Augstākais 67 USD

Zemākais 63 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Sanofi — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

3

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

53.98 / 55.4Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Strong Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.